Oncology Pharma Inc (ONPH)

[threewheeler]

Oncology Pharma, Inc. Narrows Focus on Funding Efforts
Press Release | 01/28/2020
San Francisco, CA, Jan. 28, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Oncology Pharma, Inc. (OTCPK: ONPH) would like to inform investors that it has completed its relationship with Tulynode Biosciences, Inc., and will be focusing on anti-cancer drugs instead of medical devices. Oncology Pharma wishes Tulynode Biosciences success.

Oncology Pharma is currently focusing all efforts on obtaining funding for Kalos Therapeutics, NanoSmart® Pharmaceuticals Inc., Diagnomics, Inc. and Ribera Solutions. Due diligence is currently underway for the funding LOI previously announced and the Company expects to issue more updates as they become available.

ABOUT ONCOLOGY PHARMA, INC.

ONCOLOGY PHARMA, INC. (OTCPK: ONPH) (the "Company") the Company is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare. https://www.otcmarkets.com/stock/ONPH/news/Oncology-Pharma-Inc-Narrows-Focus-on-Funding-Efforts?id=252383